A Phase Ib Trial Of The Cyclin-Dependent Kinase Inhibitor Dinaciclib (Dina) In Combination With Pembrolizumab (P) In Patients With Advanced Triple-Negative Breast Cancer (Tnbc) And Response Correlation With Myc-Overexpression.

Amy Jo Chien,Amelia S Gliwa, Siti Rahmaputri, Heidi F Dittrich,Melanie Catherine Majure,Hope S. Rugo,Michelle E. Melisko,Pamela N. Munster,John W. Park,Mark M. Moasser,Mehrdad Matloubian, Tasha Lea,Julia Rohrberg,Gregor Krings,Andrei Goga

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 9|浏览58

暂无评分

摘要

1076Background: Increased expression of the MYC transcriptional oncogene is found in about 70% of TNBC and is associated with poor prognosis. In MYC-overexpressing TN xenografts, CDK1 inhibition wi...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要